Testing effectiveness (Phase 2)WithdrawnNCT01015521What this trial is testingEfficacy Study of Aminoflavone Prodrug to Treat Breast CancerWho this might be right forBreast Neoplasm Tigris Pharmaceuticals 50
Testing effectiveness (Phase 2)Ended earlyNCT01217411What this trial is testingRO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerWho this might be right forAdult Solid NeoplasmExtensive Stage Lung Small Cell CarcinomaHER2/Neu Negative+10 more National Cancer Institute (NCI) 5
Not applicableEnded earlyNCT03619044What this trial is testingThe Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.Who this might be right forHER2-positive Breast Cancer Institut Claudius Regaud 4
Not applicableUnknownNCT05135104What this trial is testingStudy Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up PeriodWho this might be right forMetastatic Breast Cancer Asociatia Oncohelp - Centrul de Oncologie Oncohelp 650
Testing effectiveness (Phase 2)Ended earlyNCT02273752What this trial is testingPharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerWho this might be right forEstrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more Emory University 2
Not applicableEnded earlyNCT05068726What this trial is testingClinical Utility of FES F18 PET/CT in Metastatic Breast Cancer PatientsWho this might be right forMetastatic Breast Cancer GE Healthcare 51
Testing effectiveness (Phase 2)UnknownNCT04669587What this trial is testingER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Who this might be right forEstrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more EnhancedBio USA Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT02202746What this trial is testingAssess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerWho this might be right forBreast CancerMetastatic Breast CancerMBC+5 more Clovis Oncology, Inc. 178
Not applicableStudy completedNCT00115505What this trial is testingQuality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast CancerWho this might be right forBreast Carcinoma Alliance for Clinical Trials in Oncology 307
Early research (Phase 1)Study completedNCT01344031What this trial is testingMK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerWho this might be right forEstrogen Receptor PositiveInvasive Breast CarcinomaRecurrent Breast Carcinoma+1 more National Cancer Institute (NCI) 31
Early research (Phase 1)Study completedNCT02123823What this trial is testingBI 836845 in Estrogen Receptor Positive Metastatic Breast CancerWho this might be right forNeoplasms Boehringer Ingelheim 164
Testing effectiveness (Phase 2)Study completedNCT02291913What this trial is testingEverolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerWho this might be right forBreast Cancer SCRI Development Innovations, LLC 48
Testing effectiveness (Phase 2)Ended earlyNCT04675827What this trial is testingDe-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeWho this might be right forHER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast Cancer+1 more Jules Bordet Institute 139
Not applicableEnded earlyNCT02823262What this trial is testingA Breast Cancer Treatment Decision Aid for Women Aged 70 and OlderWho this might be right forBreast CancerEstrogen Receptor Positive Breast CancerNode-negative Breast Cancer+1 more Beth Israel Deaconess Medical Center 65
Large-scale testing (Phase 3)Study completedNCT01740427What this trial is testingPalbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)Who this might be right forBreast Neoplasms Pfizer 666
Large-scale testing (Phase 3)Study completedNCT00004205What this trial is testingLetrozole or Tamoxifen in Treating Postmenopausal Women With Breast CancerWho this might be right forBreast Cancer ETOP IBCSG Partners Foundation 8,028
Testing effectiveness (Phase 2)Looking for participantsNCT05766410What this trial is testingStudy Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCWho this might be right forBreast CancerHormone Receptor-positive Breast CancerHormone Therapy National Taiwan University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT00546156What this trial is testingPreoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast CancerWho this might be right forBreast Cancer Ian E. Krop, MD, PhD 104
Testing effectiveness (Phase 2)Looking for participantsNCT06525766What this trial is testingAdaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more Mayo Clinic 35
Not applicableNot Yet RecruitingNCT07387861What this trial is testingPI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic StudyWho this might be right forBreast Cancer - ER+, HER2-, PIK3CA Gene Mutation Assiut University 70